Please verify that you are a Healthcare Professional. Register for complete access to all the content!
Exploring the causal link between menarche onset a...
Age at menarche is increasingly recognized as an important reproductive factor associated with long-term metabolic and gastrointestinal health ou...
Clinical outcomes of RefluxStop for gastroesophage...
Gastroesophageal reflux disease (GERD) is a chronic, multifactorial disorder that can be challenging to tackle with long-term medical therapy alo...
1 min
Exploring the causal link between menarche onset and risk of gall...
Earlier age at menarche increases the risk of gallstone disease, with liver function, lipid metabolism, and body fat acting as key mediators.
Clinical outcomes of RefluxStop for gastroesophageal reflux disea...
RefluxStop markedly reduces GERD-HRQL scores while maintaining a 95.5% patient satisfaction rate.
Fidaxomicin is a novel macrocyclic macrolide antibiotic and the first member of a new class of antimicrobial agents.
Multi-strain probiotics as nutritional therapy for chronic consti...
A 28-day multi-strain probiotic regimen significantly improves digestive health and constipation-related symptoms in middle-aged and older adults...
Nitazoxanide-based regimens outperform standard triple therapy in...
Compared to standard triple therapy, nitazoxanide-based therapy effectively improves H. pylori elimination rates.
Non-invasive biomarkers in liver fibrosis and transplant outcomes
Serum leptin, vitamin D, and APRI serve as dynamic non-invasive biomarkers reflecting liver fibrosis severity and recovery following liver transp...
Tegoprazan emerges as fast-acting alternative to PPIs for GERD ma...
Tegoprazan delivers faster acid suppression and superior nocturnal symptom control with non-inferior healing versus PPIs in GERD.
Tradipitant is a centrally acting antiemetic approved by the Food and Drug Administration (FDA) on 30 December 2025 for the prevention of motion...
PCABs offer superior clinical outcomes across major acid-related...
PCABs deliver faster and more consistent acid suppression with comparable or superior clinical outcomes than PPIs in acid-related diseases.
Bee allergy linked to higher H. pylori infection and gastric infl...
Bee allergy significantly correlates with higher H. pylori infection rates and increased gastric inflammation.
High-dose vs. conventional therapy for H. pylori eradication
High-dose PPI–based 10-day concomitant therapy achieves the highest H. pylori eradication rate when compared to standard and reduced-durati...
Reflux oesophagitis risk factors: The hidden role of common medic...
Patients taking calcium channel blockers, theophylline, or NSAIDs face a higher likelihood of reflux oesophagitis.